Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Prostate Cancer

Free Subscription Articles published in Oncol Rep Retrieve available abstracts of 31 articles: HTML format

Single Articles

June 2024
1. LIU Y, Qin Z, Yang K, Liu R, et al
   [Corrigendum] Cripto?1 promotes epithelial?mesenchymal transition in prostate cancer via Wnt/beta?catenin signaling.
   Oncol Rep. 2024;51:75.
   PubMed     Abstract available
   
   
   May 2024
2. HSIA YJ, Lin ZM, Zhang T, Chou TC, et al
   Butyrate increases methylglyoxal production through regulation of the JAK2/Stat3/Nrf2/Glo1 pathway in castration?resistant prostate cancer cells.
   Oncol Rep. 2024;51:71.
   PubMed     Abstract available
   
   
   March 2024
3. PARAJULI KR, Jung Y, Taichman RS
   Abscisic acid signaling through LANCL2 and PPARgamma induces activation of p38MAPK resulting in dormancy of prostate cancer metastatic cells.
   Oncol Rep. 2024;51:39.
   PubMed     Abstract available
   
   
   January 2024
4. LEE DY, Chun JN, So I, Jeon JH, et al
   Oncogenic role of FOXM1 in human prostate cancer (Review).
   Oncol Rep. 2024;51:15.
   PubMed     Abstract available
   
   
   December 2023
5. LEE DY, Lee S, Kim YS, Park S, et al
   Cyclosporin A inhibits prostate cancer growth through suppression of E2F8 transcription factor in a MELK?dependent manner.
   Oncol Rep. 2023;50:218.
   PubMed     Abstract available
   
   
   September 2023
6. JI J, Shen I, Li Y, Liu Y, et al
   [Corrigendum] CDCA5 promotes the progression of prostate cancer by affecting the ERK signalling pathway.
   Oncol Rep. 2023;50:165.
   PubMed     Abstract available
   
   
   June 2023
7. XIA B, Wang J, Zhang D, Hu X, et al
   The human microbiome links to prostate cancer risk and treatment (Review).
   Oncol Rep. 2023;49:123.
   PubMed     Abstract available
   
   
   May 2023
8. SOUZA DS, Macheroni C, Vicente CM, Cavalheiro RP, et al
   Estrogen receptors regulate galectin‑3 in androgen‑independent DU‑145 prostate cancer cells.
   Oncol Rep. 2023;49:93.
   PubMed     Abstract available
   
   
   April 2023
9. CAI C, He H, Duan X, Wu W, et al
   [Corrigendum] miR‑195 inhibits cell proliferation and angiogenesis in human prostate cancer by downregulating PRR11 expression.
   Oncol Rep. 2023;49:70.
   PubMed     Abstract available
   
   
   March 2023
10. KOU B, Liu W, Zhao W, Duan P, et al
    [Corrigendum] Thymoquinone inhibits epithelial‑mesenchymal transition in prostate cancer cells by negatively regulating the TGF‑beta/Smad2/3 signaling pathway.
    Oncol Rep. 2023;49:54.
    PubMed     Abstract available
    
    
    
11. XIE H, Zhao J, Wan J, Zhao J, et al
    [Corrigendum] Long non‑coding RNA AC245100.4 promotes prostate cancer tumorigenesis via the microRNA‑145‑5p/RBBP5 axis.
    Oncol Rep. 2023;49:62.
    PubMed     Abstract available
    
    
    January 2023
12. WANG H, Zhang M, Lu W, Yuan C, et al
    Prostate cancer cell‑derived spondin 2 boosts osteogenic factor levels in osteoblasts via the PI3K/AKT/mTOR pathway.
    Oncol Rep. 2023;49:23.
    PubMed     Abstract available
    
    
    December 2022
13. SUN W, Li L, Du Z, Quan Z, et al
    [Corrigendum] Combination of phospholipase Cepsilon knockdown with GANT61 sensitizes castrationresistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway.
    Oncol Rep. 2022;48.
    PubMed     Abstract available
    
    
    
14. PU J, Li T, Liu N, Luo C, et al
    [Corrigendum] PLCepsilon knockdown enhances the radiosensitivity of castrationresistant prostate cancer via the AR/PARP1/DNAPKcs axis.
    Oncol Rep. 2022;48.
    PubMed     Abstract available
    
    
    November 2022
15. CHEN J, Xu D, Wang T, Yang Z, et al
    HMGB1 promotes the development of castrationresistant prostate cancer by regulating androgen receptor activation.
    Oncol Rep. 2022;48.
    PubMed     Abstract available
    
    
    October 2022
16. YIN B, Liu Z, Wang Y, Wang X, et al
    [Corrigendum] RON and cMet facilitate metastasis through the ERK signaling pathway in prostate cancer cells.
    Oncol Rep. 2022;48.
    PubMed     Abstract available
    
    
    August 2022
17. MENDEZ-CLEMENTE A, Bravo-Cuellar A, Gonzalez-Ochoa S, Santiago-Mercado M, et al
    Dual STAT3 and IL6R inhibition with stattic and tocilizumab decreases migration, invasion and proliferation of prostate cancer cells by targeting the IL6/IL6R/STAT3 axis.
    Oncol Rep. 2022;48.
    PubMed     Abstract available
    
    
    July 2022
18. LIN J, Chen Z, Li Z, Nong D, et al
    [Corrigendum] Screening of hub genes and evaluation of the growth regulatory role of CD44 in metastatic prostate cancer.
    Oncol Rep. 2022;48.
    PubMed     Abstract available
    
    
    May 2022
19. XU T, Liu Y, Schulga A, Konovalova E, et al
    Epithelial cell adhesion moleculetargeting designed ankyrin repeat proteintoxin fusion Ec1LoPE exhibits potent cytotoxic action in prostate cancer cells.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    
20. CHEN F, Lu Z, Deng J, Han X, et al
    [Corrigendum] SPAG9 expression is increased in human prostate cancer and promotes cell motility, invasion and angiogenesis in vitro.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    February 2022
21. GU P, Zhang M, Zhu J, He X, et al
    Suppression of CDCA3 inhibits prostate cancer progression via NFkappaB/cyclin D1 signaling inactivation and p21 accumulation.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    January 2022
22. LIU J, Zhang Y, Li S, Sun F, et al
    Androgen deprivationinduced OPHN1 amplification promotes castrationresistant prostate cancer.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    December 2021
23. CHEN B, Bai G, Ma X, Tan L, et al
    MicroRNA1955p is associated with cell proliferation, migration and invasion in prostate cancer and targets MIB1.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    
24. ZHAO J, Li Q, Feng B, Wei D, et al
    MicroRNA149 inhibits cancer cell malignant phenotype by regulating Akt1 in C42 CRPC cell line.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    November 2021
25. SHENG W, Xu W, Ding J, Li L, et al
    Curcumol inhibits the malignant progression of prostate cancer and regulates the PDK1/AKT/mTOR pathway by targeting miR9.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    September 2021
26. DU W, Li D, Xie J, Tang P, et al
    miR3673p downregulates Rab23 expression and inhibits Hedgehog signaling resulting in the inhibition of the proliferation, migration, and invasion of prostate cancer cells.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    
27. LIN J, Chen Z, Li Z, Nong D, et al
    Screening of hub genes and evaluation of the growth regulatory role of CD44 in metastatic prostate cancer.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    August 2021
28. TORRES MJ, Lopez-Moncada F, Herrera D, Indo S, et al
    Endothelin-1 induces changes in the expression levels of steroidogenic enzymes and increases androgen receptor and testosterone production in the PC3 prostate cancer cell line.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    July 2021
29. LI JM, Lee S, Zafar R, Shin E, et al
    Sodium bicarbonate transporter NBCe1 regulates proliferation and viability of human prostate cancer cells LNCaP and PC3.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    March 2021
30. ZHU J, Qin P, Cao C, Dai G, et al
    Use of miR‑145 and testicular nuclear receptor 4 inhibition to reduce chemoresistance to docetaxel in prostate cancer.
    Oncol Rep. 2021;45:963-974.
    PubMed     Abstract available
    
    
    
31. JI J, Shen T, Li Y, Liu Y, et al
    CDCA5 promotes the progression of prostate cancer by affecting the ERK signalling pathway.
    Oncol Rep. 2021;45:921-932.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.